These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 35461262)
1. Efficacy and safety of scopolamine compared to placebo in individuals with bipolar disorder who are experiencing a depressive episode (SCOPE-BD): study protocol for a randomised double-blind placebo-controlled trial. Miravalles C; Kane R; McMahon E; McDonald C; Cannon DM; Hallahan B Trials; 2022 Apr; 23(1):339. PubMed ID: 35461262 [TBL] [Abstract][Full Text] [Related]
3. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Furey ML; Drevets WC Arch Gen Psychiatry; 2006 Oct; 63(10):1121-9. PubMed ID: 17015814 [TBL] [Abstract][Full Text] [Related]
4. A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder. Chen JCC; Sumner RL; Krishnamurthy Naga V; Hoeh N; Ayeni HA; Singh V; Sundram F; Campbell D; Muthukumaraswamy S Trials; 2020 Feb; 21(1):157. PubMed ID: 32041658 [TBL] [Abstract][Full Text] [Related]
5. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. McCloud TL; Caddy C; Jochim J; Rendell JM; Diamond PR; Shuttleworth C; Brett D; Amit BH; McShane R; Hamadi L; Hawton K; Cipriani A Cochrane Database Syst Rev; 2015 Sep; (9):CD011611. PubMed ID: 26415966 [TBL] [Abstract][Full Text] [Related]
6. ECNP consensus meeting. Bipolar depression. Nice, March 2007. Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566 [TBL] [Abstract][Full Text] [Related]
7. Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression. Yatham LN; Arumugham SS; Kesavan M; Ramachandran K; Murthy NS; Saraf G; Ouyang Y; Bond DJ; Schaffer A; Ravindran A; Ravindran N; Frey BN; Daigneault A; Beaulieu S; Lam RW; Kondapuram N; Reddy MS; Bhandary RP; Ashok MV; Ha K; Ahn YM; Milev R; Wong H; Reddy YCJ; N Engl J Med; 2023 Aug; 389(5):430-440. PubMed ID: 37530824 [TBL] [Abstract][Full Text] [Related]
8. Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial. Petersen JZ; Schmidt LS; Vinberg M; Jørgensen MB; Hageman I; Ehrenreich H; Knudsen GM; Kessing LV; Miskowiak KW Trials; 2018 Nov; 19(1):611. PubMed ID: 30400939 [TBL] [Abstract][Full Text] [Related]
9. Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Furey ML; Khanna A; Hoffman EM; Drevets WC Neuropsychopharmacology; 2010 Nov; 35(12):2479-88. PubMed ID: 20736989 [TBL] [Abstract][Full Text] [Related]
10. [Interest of scopolamine as a treatment of major depressive disorder]. Rigal A; Mouchabac S; Peretti CS Encephale; 2016 Dec; 42(6):568-573. PubMed ID: 27623122 [TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
12. Therapy of replenishing and regulating for manic episode in bipolar disorder: study protocol for a prospective, double-blind, randomized controlled trial. Yang Y; Haining Y; Hongxiao J; Yanzhe N; Di W; Lei Z; Kaijuan Y; Yumeng G; Fei W; Weishuang S; Pei C J Tradit Chin Med; 2023 Jun; 43(3):594-601. PubMed ID: 37147763 [TBL] [Abstract][Full Text] [Related]
13. Letter to the Editor: CONVERGENCES AND DIVERGENCES IN THE ICD-11 VS. DSM-5 CLASSIFICATION OF MOOD DISORDERS. Cerbo AD Turk Psikiyatri Derg; 2021; 32(4):293-295. PubMed ID: 34964106 [TBL] [Abstract][Full Text] [Related]
14. A Randomized Controlled Trial of Intravenous Scopolamine Versus Active-Placebo Glycopyrrolate in Patients With Major Depressive Disorder. Chen JCC; Sumner RL; Naga VK; Hoeh N; Ayeni HA; Singh V; Wilson A; Campbell D; Sundram F; Muthukumaraswamy SD J Clin Psychiatry; 2022 Aug; 83(5):. PubMed ID: 35980261 [No Abstract] [Full Text] [Related]
15. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. Calabrese JR; Ketter TA; Youakim JM; Tiller JM; Yang R; Frye MA J Clin Psychiatry; 2010 Oct; 71(10):1363-70. PubMed ID: 20673554 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial. Calabrese JR; Frye MA; Yang R; Ketter TA; J Clin Psychiatry; 2014 Oct; 75(10):1054-61. PubMed ID: 25099397 [TBL] [Abstract][Full Text] [Related]
17. Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study). Azim L; Hindmarch P; Browne G; Chadwick T; Clare E; Courtney P; Dixon L; Duffelen N; Fouweather T; Geddes JR; Goudie N; Harvey S; Helter T; Holstein EM; Martin G; Mawson P; McCaffery J; Morriss R; Simon J; Smith D; Stokes PRA; Walker J; Weetman C; Wolstenhulme F; Young AH; Watson S; McAllister-Williams RH BMC Psychiatry; 2021 Jul; 21(1):334. PubMed ID: 34225686 [TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
19. [Early intervention in bipolar affective disorders: Why, when and how]. Pouchon A; Fakra E; Haesebaert F; Legrand G; Rigon M; Schmitt E; Conus P; Bougerol T; Polosan M; Dondé C Encephale; 2022 Feb; 48(1):60-69. PubMed ID: 34565543 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study. Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; Salzman PM; McQuade RD; Nyilas M; Carson WH J Clin Psychiatry; 2017 Mar; 78(3):324-331. PubMed ID: 28146613 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]